The PD-1 track "inner roll" is still intensifying!

【Pharmaceutical Network Market Analysis】As of the end of June 2022, there are 8 domestic PD-1 products that have been approved for listing in the domestic market
.

As more and more pharmaceutical companies enter the PD-1 field, the "inner volume" of this market competition continues to intensify
.

Hengrui Pharmaceutical, BeiGene Shenzhou, Junshi Biologics, and Cinda Biologics are known as PD-1 Four Xiaolong, and the data shows that in the first half of 2022, the four companies achieved a total operating income of 17.
624 billion yuan, a year-on-year decrease of 20.
77%; The total net profit attributable to the mother was -6.
407 billion yuan, which was also an increase
compared with the net loss of the same period last year.

Tirelizumab BeiGene's PD-1 product Baizean (Tirelizumab injection) achieved a total sales volume of 1.
251 billion yuan in the first half of the year, standing out among the PD-1 four dragons
.

At the performance communication meeting on August 31, the company said that after the expansion of the scope of medical insurance reimbursement, it has brought about new patient demand and continued to improve the market penetration rate
of Bazawa An in approved indications.

The Company expects revenue to continue to grow well
.

Triprilizumab Thanks to the expansion of the sales team in the first half of the year, as of the end of June, the company's commercialization team exceeded 1,100 people, and the company's commercialization speed accelerated
.

Among them, the sales revenue of the core product PD-1 Tuoyi (terreprimumab injection) was about 298 million yuan, an increase of about 196%
over the second half of 2021.

Recently, the company's management said at the three-quarter performance telephone communication meeting that due to few indications, relatively low prices, and personnel factors, PD-1 sales this year were poor
.

Improvements are expected next year, with a sales target of RMB
1.
5 billion.

Carellilizumab Hengrui Pharmaceutical mentioned in the 2021 semi-annual report that Carellilizumab began to implement the medical insurance negotiation price since March 1, 2021, a decrease of 85%, coupled with many problems such as the difficulty of entering the hospital and the different implementation time of medical insurance in various places, resulting in a negative growth in
sales revenue of carilizumab.

As of now, Hengrui has not announced the sales amount
of Erica (carilizumab for injection) in the third quarter.

However, at the recent performance exchange meeting, when asked about the volume of PD-1, the management replied that "the volume is growing, but the price of medical insurance has been reduced by 85%, and the revenue growth rate is limited.
"

Previously, the company replied to investors on the interactive platform that the company has listed ten innovative drugs, and the company will continue to focus on the optimization and improvement of the product structure, and drive performance growth
by promoting the release of ten innovative drugs that have been approved for listing and promoting the listing of more innovative drugs.

Xindilimumab According to the disclosure of Lilly, due to the impact of medical insurance price cuts, the epidemic and the adjustment of the company's commercialization team, the sales revenue of Daboshu (Xindilizumab injection) of Cinda Bio in the first half of 2022 was US$159 million, a year-on-year decrease of 26%
compared with the same period last year.

However, CMB International released a research report saying that it is expected that the sales of Xindilizumab will be better than in the first half of the year
.

Conclusion Overall, affected by intensified competition, medical insurance price reduction, environment and other factors, the amount of PD-1 and sales revenue of many pharmaceutical companies in the first half of the year have declined, but in the long run, many companies still say that they are optimistic about their products, such as Junshi Bio said in the semi-annual report, "At present, Tuoyi's sales in China have gradually recovered and begun to enter a positive cycle, and the company is full of confidence in
future commercialization work.
"
It is reported that Junshi Bio is still actively promoting research and development projects according to the process, as of the end of June, the company is in the commercialization stage of 3 products under research, nearly 30 products under research are in the clinical trial stage, more than 20 products under research are in the preclinical development stage, covering small molecules, polypeptides, ADCs, double or multispecific antibodies, nucleic acids and other types of drugs
.

Disclaimer: Under no circumstances does the information herein or the opinions expressed in this article constitute investment advice
to any person.